Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2018-08-10 Interim / Quarterly Rep…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
2018年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2018 年半年度报告" which translates to "2018 Semi-Annual Report". It contains detailed financial data, business overview, management discussion and analysis, and operational performance for the first half of 2018. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data. The content includes sections such as company overview, financial indicators, business segments, risk factors, and management discussion, which are typical of an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2018
2018-08-10 Chinese
八届五十四次董事会决议公告
Board/Management Information Classification · 95% confidence The document is a board resolution announcement from Kunming Pharmaceutical Group Co., Ltd. It details the decisions made at the 54th meeting of the 8th board of directors, including approval of the 2018 semi-annual report and other proposals. The document includes voting results and references to other announcements and reports but does not contain the actual semi-annual report or detailed financial data itself. The document is relatively short (1433 characters) and serves as an official announcement of board meeting resolutions and voting outcomes. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2018-08-10 Chinese
八届二十八次监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the supervisory board of Kunming Pharmaceutical Group Co., Ltd. It details the approval of the 2018 semi-annual report and related matters such as the use of raised funds and stock repurchase plans. The document is short (1043 characters) and primarily announces the decisions made by the supervisory board rather than containing the full semi-annual report or detailed financial data. It fits the category of a regulatory announcement related to board or management decisions, specifically the supervisory board's resolutions. Therefore, it is best classified under Regulatory Filings (RNS) as it does not contain the full interim report itself but rather the supervisory board's approval and related resolutions.
2018-08-10 Chinese
关于拟回购并注销2017年限制性股票激励计划离职激励对象已获授但尚未解除限售部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is an official announcement from Kunming Pharmaceutical Group Co., Ltd. regarding the proposed repurchase and cancellation of restricted shares granted under the 2017 restricted stock incentive plan to employees who have left the company. It details the background of the stock incentive plan, the reasons for repurchase, the number of shares involved, the repurchase price, and the impact on the company's share capital structure. It also includes opinions from the independent directors, supervisory board, and legal counsel, and outlines the next steps including shareholder approval. The document is a formal disclosure about a share repurchase and cancellation related to the company's stock incentive plan, which fits the category of Transaction in Own Shares (POS). The document length is 3151 characters, which is sufficient to be a full announcement rather than a brief notice. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing or report publication announcement. Therefore, the most appropriate classification is POS (Transaction in Own Shares).
2018-08-10 Chinese
关于授权昆药集团医药商业有限公司为曲靖市康桥医药有限责任公司1000万元银行综合授信额度提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by Kunming Pharmaceutical Group Co., Ltd. regarding the authorization of a subsidiary to provide a bank guarantee for another affiliated company. It details the guarantee amount, the parties involved, the board's opinion, and the need for shareholder approval. There are no financial statements, earnings data, or detailed financial reports included. The document is an announcement about a financing-related guarantee and does not contain comprehensive financial data or results. It fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees.
2018-08-10 Chinese
2018年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a "2018 年半年度报告摘要" which translates to "2018 Half-Year Report Summary." It contains detailed financial data for the first half of 2018, including total assets, net profit, earnings per share, and operational analysis. It discusses business segments, investment and acquisition activities, R&D progress, and quality management. The document is about a half-year period and includes substantive financial data and analysis, not just an announcement or summary without data. Therefore, it fits the definition of an Interim / Quarterly Report (IR). The document length is 7397 characters, which is sufficient to contain detailed financial information rather than just a brief announcement. Hence, the classification is IR with high confidence. H1 2018
2018-08-10 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.